A prospective study of the use of 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors.
- Conditions
- Patients with neuroendocrine tumors, who are going to be diagnosed/evaluated with 68Ga-DOTA-TATE PET/CT instead of standard OctreoscanMedDRA version: 14.1Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 100000004864Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Registration Number
- EUCTR2012-004313-13-SE
- Lead Sponsor
- Skåne University Hospital, Dept of Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
Age 18 years or more
Signed written informed concent
Follow up of previous diagnosed neuroendocrine tumor or is under investigation for suspect neuroendocrine tumor
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 135
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 315
Exclusion Criteria
Pregnancy or breastfeeding
Age less than 18 years
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method